Dr. Marty Giedlin, PhD
Senior Vice President and Head of Technical Operations, Senti BioSciences
Dr. Giedlin is currently the VP, Head of Technical Operations at Senti BioSciences supporting the allogeneic CAR NK cell programs. Before his joining Senti BioSciences, he led the PD groups at PACT Pharma (non-viral process for generating autologous neoTcR+ T cells), Poseida (non-viral process for generating autologous CAR Ts), and Novartis (clinical and commercial manufacturing process for Kymriahâ). His experience covers over 25 years of various approaches to harness the immune response to treat cancer and infectious disease, starting with Proleukinâ rIL-2 (aldesleukin; Chiron), Oncolytic adenovirus (Onyx), Listeria-based cancer vaccines (Cerus), and CCR5 knockout CD4+ T cells for HIV+ patients (Sangamo). In addition, he led the implementation of AAV clinical manufacturing to support the Hemophilia, LSD, and neurodegenerative disease programs.
Got a question for Dr. Marty Giedlin, PhD?
Get in touch using the contact form linked here and we’ll get back to you shortly
